Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARP1
- Development stage
- Phase 2
- Lead developer
- icddr,b
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Oral
01
Overview
ARP1 (Anti-Rotavirus Protein 1) is a llama-derived, recombinant monovalent heavy-chain antibody fragment (VHH) developed by the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B) in collaboration with Unilever Research and Development. It specifically targets the VP6 protein, a highly conserved and abundant middle-layer protein of the rotavirus, which allows it to neutralize a broad range of rotavirus serotypes and genotypes. Administered orally, ARP1 is designed to treat rotavirus-induced gastroenteritis in infants and children. It is characterized by high stability and resistance to gastric acid, facilitating its delivery to the gut. Clinical studies, including a Phase 2 trial, have demonstrated its efficacy in reducing stool output and the duration of diarrhea in male infants with severe rotavirus infection. The antibody fragment has been produced in various expression systems, including yeast, rice (MucoRice-ARP1), and Lactobacillus.
- Other names
- Anti-Rotavirus Protein 1llama-derived anti-rotavirus VHH fragmentMucoRice-ARP1MucoRice-ARP-1MucoRice-ARP 1
02
Targets
VP6 (Rotavirus capsid protein VP6)
Beyond the preview
Go deeper on ARP1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARP1.